Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Omnicare acquires Advanced Care Scripts
The transaction is expected to be modestly accretive to Omnicare’s earnings in 2008, with accretion expected to increase in 2009 and beyond. Joel Gemunder, president and CEO of
The transaction is expected to be modestly accretive to Omnicare’s earnings in 2008, with accretion expected to increase in 2009 and beyond. Joel Gemunder, president and CEO of
Immunosyn is negotiating an exclusive license agreement for the administration and distribution of SF-1019 in the State of Utah with Utah Biopharmaceutical Laboratories. Immunosyn has been advised by
In addition to serving the Middle East and North African (MENA) countries with marketing and distribution of company owned and developed products, Generex MENA also identifies other complimentary
According to Iris, iQ200 uses Auto-Particle Recognition, a well-trained neural network, to classify and quantitate 12 formed elements with true image morphology and walkway capability, providing the highest
Up to 55 RhD-positive adult non-splenectomized patients with idiopathic thrombocytopenic purpura (ITP) will be enrolled in this first exploratory open label safety, efficacy and dose-finding trial. The study
The top-line analysis of data from this study shows that Prulifloxacin met the primary endpoint of time to last unformed stool (TLUS) in both the mITT (modified intent-to-treat;
Under the agreement, EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-investigational new drug (IND)
Under the terms of the agreement, Theragenics will pay $47.8 million in cash, plus transaction costs, for NeedleTech, subject to the terms and conditions of the agreement. Theragenics
Under the agreement, the company purchased back 49% of the drug agency and distribution right from Ophol, for an ongoing royalty payment of RMB6 million per year. The
The single-center trial called NeoACT, or P07-1 has started enrolling approximately 40 patients. NeoACT is the first of two new Phase II trials of Provenge being initiated in